Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) repurchased 85,800 H-shares on 08 September 2026 via on-market transactions, paying a total of HK$1.37 million at prices ranging from HK$15.81 to HK$16.45 per share. The volume-weighted average price was HK$16.01.

Following the transaction, the company’s outstanding share count (excluding treasury shares) decreased by 0.06% to 151.54 million, while treasury shares grew to 2.79 million. Total issued shares remained unchanged at 154.33 million.

The buyback was executed under the mandate approved on 26 May 2026, which authorises the repurchase of up to 15.43 million shares. To date, Bao Pharma has repurchased 2.79 million shares, representing 1.81% of the issued share capital at the time the mandate was granted.

In line with Hong Kong Stock Exchange regulations, the company is subject to a moratorium on issuing, selling or transferring any treasury shares until 08 October 2026.